Physician profile
Fadi Oska
NPI 1205856432
$8,610.14
in general payments reported to CMS, 2019-2025
42 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $371 · 2021: $206 · 2022: $1,616 · 2023: $1,587 · 2024: $2,089 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,368.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,347.16 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,004.63 | 2019-2025 | Repatha, Krystexxa, Evenity |
| Lilly USA, LLC | $892.69 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $724.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $579.77 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $442.04 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Abbvie INC. | $426.18 | 2022-2025 | |
| Glaxosmithkline, LLC. | $389.66 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $340.43 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $301.65 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $263.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $187.46 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.11 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $151.52 | 2019-2025 | Gattex, Trintellix |
| Exact Sciences Corporation | $130.40 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Oska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.